Good MorningThe equities markets got a boost on Friday after a stronger than expected non-farm payrolls report. The headline figure of 4.8 million was far above analysts’ estimates and has added fuel to the market’s melt-up. The down shot is that news related to the COVID-19 pandemic helped cap gains. Word of new record levels of cases in the U.S. has the markets worried about another round of economic interruption and the impact on earrings.
Despite the worry, Friday’s action was bullish as it set a new high and closed above the previous day’s action. The candle, a small doji, is a sign of indecision but one that will likely lead to higher prices over the next few weeks. With the reopening underway, economic data is going to be strong and that will drive bullish sentiment as the 2nd quarter earnings cycle gets underway.
Featured: The Marijuana Gold Rush Is Here... (Profits Run) 
|
Markets | | |
It’s safe to say that the short term impact of the global pandemic on the commercial retail sector has been devastating. With malls forced to shut down for an extended period of time and more and more consumers shifting towards online shopping, times are tough for major mall owners. Simon Pr... Read the Full Story |
|
|
Stocks | | | Fast-Food Is Rebounding Fast
Restaurant stocks, specifically fast-food restaurant stocks and/or those with a drive-through or delivery presence, have been doing well in the post-pandemic world. The data shows a bottom was hit in March and sales have only been accelerating since. Based on the data a... Read the Full Story |
|
Markets | | | E-commerce stocks are arguably seeing a 1999-like bubble as the COVID-10 pandemic has bestowed a halo effect on companies with frictionless transactions coupled with a network effect. Online marketplace Etsy, Inc. (NASDAQ: ETSY) enables individuals and businesses to auction, buy and sell unique cust... Read the Full Story |
|
Markets | | | Pharmaceutical giant Pfizer (NYSE: PFE) got off to a good start in Q3 with a 5% gap up to start Wednesday’s session. Shares were popular on Wall Street after positive results from a coronavirus vaccine trial were released. It’s still early days, with only 45 patients taking part, but sti... Read the Full Story |
|
Markets | | | Stunning News, To Say The Least
The market just received a stunning jobs report but I can’t say that I am surprised. The consensus target for this month was way too low considering the environment we are in. This is not like any ordinary recession we have ever seen. There was no collapse of b... Read the Full Story |
|
From Our PartnersAmerica's $51 trillion recovery will be of unheard magnitude.
Only it's not from a single thing the government is doing. Or even from big corporations.
Instead, it's due to one tiny pioneering American company.
You won't believe what this made-in-America device does.
It's poised to create more millionaires than pot stocks, cryptos and Big Tech - combined! | | Click here for the full story. |
|
The Early Bird Stock Of The Day Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland. | | View Today's Stock Pick |
|
